The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
This product has sales of about US$ 20 million in Europe
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Furthering cell therapy ambition across oncology and autoimmune diseases
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Advances clinical research capabilities with leading regulatory grade registries platform
Subscribe To Our Newsletter & Stay Updated
